Zusammenfassung
Hintergrund
Der plötzliche Herztod gehört zu den führenden Todesursachen in der westlichen Welt. Ein kleines Kollektiv scheinbar gesunder Menschen erleidet den plötzlichen Herztod, ohne dass eine strukturelle Herzerkrankung zugrunde liegt. Bei diesen Patienten ist nicht selten der plötzliche Herztod das erste Anzeichen der Erkrankung. Es stellt eine große Herausforderung dar, gefährdete Patienten frühzeitig zu identifizieren und vor Auftreten des ersten lebensbedrohlichen Ereignisses vor dem plötzlichen Herztod zu schützen.
Ursachen
Zu den sog. elektrischen Erkrankungen gehören das lange QT-Syndrom, das kurze QT-Syndrom, das Brugada-Syndrom, die katecholaminerge polymorphe ventrikuläre Tachykardie. Auch das Wolff-Parkinson-White-Syndrom kann sich in seltenen Fällen durch einen plötzlichen Herztod manifestieren. Ein erhöhtes Risiko zum Erleiden des plötzlichen Herztodes kann bei entsprechendem Risikoprofil außerdem durch Drogen bzw. Medikamente verursacht werden.
Prävention
Der Defibrillator bietet zum heutigen Zeitpunkt den einzigen sicheren Schutz vor dem plötzlichen Herztod. Innovative subkutane Defibrillatoren können eine attraktive Alternative gegenüber den konventionellen transvenösen Systemen für diese meist jungen Patienten darstellen.
Ziel
Ziel dieses Beitrages ist es, die für das Auftreten des plötzlichen Herztodes ursächlichen Erkrankungen näher zu beleuchten sowie Hinweise zu geben, wie Risikopatienten identifiziert und behandelt werden können.
Abstract
Background
Sudden cardiac death (SCD) is one of the major causes of death in the industrialized world. A small group of apparently healthy individuals suffer SCD without any structural heart disease as the underlying cause. Often SCD is the first symptom, hence, the majority of these patients are not protected by a defibrillator as primary prevention. It is a great challenge to identify and treat patients at risk before the first event leading to SCD occurs.
Causes
Congenital diseases are long and short QT syndromes, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia. Additionally, the Wolff-Parkinson-White (WPW) syndrome still plays a rare but important role as patients may be cured by catheter ablation. In some people with predisposing risk factors, SCD may be caused by specific drugs.
Prevention
A defibrillator is currently the only certain preventive therapy. Innovative subcutaneous defibrillators may be an attractive alternative to conventional transvenous systems for high-risk patients.
Goal
The goal of this article is to depict the causes of SCD in patients without an underlying structural heart disease and give indications on how to identify and treat this patient group.
Literatur
Ackerman MJ, Priori SG, Willems S et al (2011) HRS/EHRA expert consensus statement on the state of genetic testing for the chennelopathies and cardiomyopathies. Europace 13:1077–1109
Alter P, Waldhans S, Pachta E et al (2005) Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol 926–932
Antz M, Weiss C, Volkmer M et al (2002) Risk of sudden death after successful accessory atrioventricular pathway ablation in resuscitated patients with Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol 13:231–236
Antzelevitch C, Brugada P, Borggrefe M et al (2005) Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 111:659–670
European Heart Rhythm Association, Heart Rhythm Society, Zipes DP et al (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death). J Am Coll Cardiol 48:e247–e346
Belhassen B, Glick A, Viskin S et al (2004) Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 110:1731–1737
Bellocq C, Van Ginneken AC, Bezzina CR et al (2004) Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 2394–2397
Brugada R, Hong K, Dumaine R et al (2004) Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 109:30–35
Chen Q, Kirsch GE, Zhang D et al (1998) Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 392:293–296
De Ponti F, Polluzzi E, Montanaro N et al (2000) QTc and psychotropic drugs. Lancet 356(9223):75–76
Frommeyer G, Pott C, Schulze- Bahr E et al (2012) Catecholaminergic polymorphic ventricular tachycardia. Herzschrittmacher Elektrophysiol 23:231–236
Haverkamp W, Breithardt G, Camm AJ et al (2000) The potential for QT prolongation and proarrhythmia by non- antiarrhythmic drugs: clinical and regulatory implications; Report on a Policy Conference of the European Society of Cardiology. Eur Heart J 1216–1231
Kirchhof P, Breithardt G, Eckardt L et al (2006) Primary prevention of sudden cardiac death. Heart 92:1873–1878
Köbe J, Zumhagen S, Reinke F et al (2011) Totally subcutaneous cardioverter-defibrillator (S-ICD®): recent experience and future perspectives. Herz 36(7):586–591
Milberg P, Tegelkamp R, Osada N et al (2007) Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome. J Cardiovasc Electrophysiol 18(6):658–664
Nademanee K, Veerakul G, Chandanamattha P et al (2011) Prevention of ventricular fibrillation episodes in Brugada syndrome by catheter ablation over the anterior right ventricular outflow tract epicardium. Circulation 123(12):1270–1279
Paediatric and Congenital Electrophysiology Society (PACES), Heart Rhythm Society (HRS), American College of Cardiology Foundation (ACCF) (2012) PACES/HRS expert consensus statement of the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation), electrocardiographic pattern: developed in partnership between the Paediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Paediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS). Heart Rhythm 9:1006–1024
Priori SG, Aliot E, Blomstrom- Lundqvist C et al (2001) Task force of sudden cardiac death of the European Society of Cardiology. Eur Heart J 1374–1450
Priori SG, Napolitano C (2004) Genetics of cardiac arrhythmias and sudden cardiac death. Ann N Y Acad Sci 1015:96–110
Priori SG, Pandit SV, Rivolta I et al (2005) A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 96(7):800–807
Reinke F, Löher A, Köbe J et al (2013) Current status and problems of the entirely subcutaneous ICD (S-ICD). Herzschrittmacher Elektrophysiol 24:165–170
Roden DM (1998) Taking the „idio“ out of „idiosyncratic“: predicting torsades de pointes. Pacing Clin Electrophysiol 21(5):1029–1034
Rolf S, Bruns HJ, Wichter T et al (2003) The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and recommended protocol. Eur Heart J 12:1104–1112
Schimpf R, Bauersfeld U, Gaita F et al (2005) Short QT syndrome: successful prevention of sudden cardiac death in an adolescent by implantable cardioverter-defibrillator treatment for primary prophylaxis. Heart Rhythm 2(4):416–417
Schwartz PJ, Locati EH, Moss AJ et al (1991) Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome. A worldwide report. Circulation 84(2):503–511
Schwartz PJ, Priori SG, Locati EH et al (1995) Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na(+) channel blockade and to increases in heart rate: implications for gene-specific therapy. Circulation 92(12):3381–3386
Tanaka Y, Yoshinaga M, Anan R et al (2006) Usefulness and cost effectiveness of cardiovascular screening of young adolescents. Med Sci Sports Exerc 38(1):2–6
Timmermans C, Smeets JL, Rodriquez LM et al (1995) Aborted sudden death in the Wolff-Parkinson-White syndrome. Am J Cardiol 76:492–494
Triggle DJ (2006) L-type calcium channels. Curr Pharm Des 12:443–457
Van Hare GF, Javitz H, Camelli D et al (2004) Prospective assessment after paediatric cardiac ablation: demographics, medical profiles, and initial outcomes. J Cardiovasc Electrophysiol 15:759–770
Van den Werf C, Zwinderman AH, Wilde AA et al (2012) Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments. Europace 14:175–183
Einhaltung ethischer Richtlinien
Interessenkonflikt. A. Fischer, K. Wasmer, F. Reinke, G. Frommeyer und L. Eckardt geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fischer, A., Wasmer, K., Reinke, F. et al. Plötzlicher Herztod ohne strukturelle Herzerkrankung. Kardiologe 8, 385–392 (2014). https://doi.org/10.1007/s12181-014-0598-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12181-014-0598-4